Tanaka K, et al. - Researchers report 10-year observation results of JCOG0304, a study with a 3-year follow-up regarding the effectiveness of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-risk soft-tissue sarcomas (STS) of the extremities. They administered 3 courses of preoperative and 2 courses of postoperative chemotherapy, containing 60 mg/m² of DXR plus 10 g/m² of IFM over a 3-week interval, in patients with operable, high-risk STS (T2bN0M0, AJCC 6th edition) of the extremities. Progression-free survival (PFS) computed by Kaplan-Meier methods was considered as the primary study endpoint. They found 10-year PFS was 65.7% (95% CI: 53.4–75.5%). During the last 5 years of follow-up, they found no PFS events. The 10-year overall survival was estimated to be 78.1% (95% CI: 66.3–86.2%). Only a few long-term consequences of clinical trials for perioperative chemotherapy treatment of STS have been documented. As per the findings, a stable 10-year outcome of JCOG0304 for patients with operable, high-risk STS of the extremities was revealed. This outcome continued to be favorable during the last 5 years of follow-up.